Bunion Treatment Market

Growing incidents of bunion is driving the market growth

The rising number of bunion people drives market CAGR for bunion (hallux valgus) treatment. One in three Americans has bunion or hallux valgus, a prevalent foot ailment in adults. The condition is most frequently brought on narrow shoes for an extended period, by wearing uncomfortable, foot injuries, and genetic foot issues.

According to a study by NCBI,63% and 74% of the participants wore shoes that were either too short or too wide, which increased their risk of developing foot issues such as bunions, calluses, and deformities. This condition is more common in older adults, especially women, because their connective tissues are weaker, and they wear tight, heeled shoes more often. Growing arthritis prevalence is predicted to affect market expansion throughout the forecast period positively.

Inflammatory disease, such as rheumatoid arthritis, increases the risk of bunions. By a Vittori essay, 90% of rheumatoid arthritis patients ly experience foot issues. In rheumatoid arthritis, the body mistakenly attacks the linings of the big toes, increasing the risk of developing a bunion. Swelling and issues with joint movement are additional symptoms of both disorders that are expected to contribute to the market's growth.

The availability of a wide range of surgical and non-surgical techniques to control the issue, such as PROstep MIS, a non-invasive process. Orthopedic implants, bunion pads and tapings, painkillers, injections, surgery, and physical therapy treat bunions. The market is predicted to rise as more operations are used to treat the illness; for example, according to a San Mateo Podiatry Group article, about 150,000 surgeries are performed annually in the United States.

Additionally, the FDA's continued approval of new products is anticipated to fuel market expansion. The prevalence of working women and changing lifestyles have increased the chance of developing a bunion (hallux valgus), which has increased the demand for bunion treatment. Every year, around 150,000 bunion surgeries are carried out in the U.S. This is anticipated to significantly stimulate the bunion correction system industry. Additionally, the industry is further boosted by the rising approvals for various corrective systems. The FDA approved using the Lapiplasty 3D Bunion Correction System for pediatric patients in May 2019.

Thus, driving the Bunion (Hallux Valgus) Treatment market revenue.

Increased awareness about bunions and their treatment options is a crucial driver for the Global Bunion (Hallux Valgus) Treatment Market Industry. Educational campaigns by healthcare providers and associations have led to greater public knowledge regarding the condition and its implications. Patients are now more informed about the available treatments, including both conservative and surgical options. This heightened awareness is likely to result in more individuals seeking medical advice and treatment, thereby expanding the market. As awareness continues to grow, it is anticipated that the demand for bunion treatments will further increase, contributing to market expansion.

Innovations in surgical procedures for bunion correction are significantly influencing the Global Bunion (Hallux Valgus) Treatment Market Industry. Minimally invasive techniques, such as the use of arthroscopy, have improved patient outcomes and reduced recovery times. These advancements not only enhance the effectiveness of treatments but also appeal to patients seeking quicker recovery. As a result, the market is projected to grow from 0.02 USD Billion in 2024 to 0.05 USD Billion by 2035, reflecting a compound annual growth rate (CAGR) of 9.34% from 2025 to 2035. This trend indicates a shift towards more efficient and patient-friendly treatment options.

The Global Bunion (Hallux Valgus) Treatment Market Industry is also being propelled by the increasing adoption of orthotic devices. These devices, which include custom insoles and bunion splints, provide non-invasive treatment options that alleviate pain and improve foot function. The growing trend towards preventive care and self-management of foot health has led to a rise in the use of these products. As consumers become more health-conscious, the demand for orthotic solutions is expected to grow. This trend is likely to contribute to the overall market growth, as more individuals seek effective, non-surgical alternatives for bunion treatment.

The Global Bunion (Hallux Valgus) Treatment Market Industry is experiencing growth due to the rising prevalence of bunions among various demographics. Factors such as aging populations and lifestyle choices contribute to this increase. For instance, bunions are more common in older adults, with studies indicating that approximately 23% of individuals aged 18-65 and 36% of those over 65 are affected. This growing incidence necessitates effective treatment options, thereby expanding the market. As the population continues to age, the demand for bunion treatments is expected to rise, further driving the market's growth.

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American Bunion (Hallux Valgus) Treatment market will dominate this market; the market in the area includes the higher prevalence of the ailment there and the accessibility of treatment centers for corrective operations.

Hence, the major countries studied in the market report are The US, Canada, German, France, the U.K., Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  BUNION (HALLUX VALGUS) TREATMENT MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Due to the expanding use of technology, the European Bunion (Hallux Valgus) Treatment market holds the second-largest market share. The market for Bunion (Hallux Valgus) Treatment in Germany had the biggest market share, and the market in the U.K. had the quickest growth rate in Europe.

The Bunion (Hallux Valgus) Treatment Market in Asia-Pacific is anticipated to see the quickest CAGR between 2023 and 2032. The rise of the regional market is predicted to be positively impacted by growing senior populations in countries like China, Japan, and India, as well as an increase in healthcare tourism. In addition, the Indian Bunion (Hallux Valgus) Treatment market had the quickest growth rate in the Asia-Pacific region. In contrast, China's Bunion (Hallux Valgus) Treatment market had the greatest market share.

Leading industry companies are making significant R&D investments to diversify their product offerings, which will expand the Bunion (Hallux Valgus) Treatment market. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants also engage in several strategic actions to increase their worldwide presence. The Bunion (Hallux Valgus) Treatment industry must produce inexpensive products to expand and survive in a more competitive and tough market climate.

Local manufacturing to minimize operating costs is one of the key business tactics manufacturers use in the  Bunion (Hallux Valgus) Treatment industry to support clients and increase the market sector. In recent years, the Bunion (Hallux Valgus) Treatment industry has offered some of the most significant advantages. Major players in the Bunion (Hallux Valgus) Treatment market, including Stryker, are attempting to increase market demand by investing in research and development operations.

Stryker, one of the top medical equipment manufacturers worldwide, is committed to improving healthcare with its clients. The business provides cutting-edge orthopedic, medical, and surgical, as well as neurotechnology and spine products and services that enhance patient and hospital results. In September 2021, The medical equipment business Gauss Surgical, which created the artificial intelligence-enabled Triton platform, was acquired by Stryker. This technology was created to track blood loss in real time during surgery. After this acquisition, Stryer sought to use this technology to enhance patient and carer safety and outcomes.

The research, production, and marketing of medical devices for use in orthopaedic reconstruction and trauma, sports medicine, ENT, and advanced wound treatment are the main business activities of Smith & Nephew Plc (Smith & Nephew). The business provides robotics-assisted technologies, knee and hip implants to replace sick, worn, or damaged joints, trauma-related items to stabilise fractures, and deformity repair operations. Additionally, it provides items for treating wounds as well as tools and materials for removing and repairing soft tissue.